AARD
Aardvark Therapeutics, Inc.
NASDAQ
| Dec 2025 | Dec 2024 | |
|---|---|---|
| Operating | ||
| Operating Cash Flow | — | — |
| Net Income | — | — |
| Depreciation & Amort. | — | — |
| Stock-Based Comp. | — | — |
| Changes in WC | — | — |
| Investing | ||
| Capital Expenditures | 95,000 | 109,000 |
| Acquisitions | — | — |
| Investing Cash Flow | — | — |
| Financing | ||
| Debt Repayment | — | — |
| Common Stock Issued | — | — |
| Buybacks | — | — |
| Dividends Paid | — | — |
| Financing Cash Flow | — | — |
| Summary | ||
| Free Cash Flow | -54.3M | -18.2M |
| Net Change in Cash | — | — |